

Mexico Cell and Gene Therapy Market Size, Share, Trends and Forecast by Therapy Type, Indication, Delivery Mode, End User, and Region, 2026-2034

<https://marketpublishers.com/r/MFC42DBF120DEN.html>

Date: June 2026

Pages: 116

Price: US\$ 3,999.00 (Single User License)

ID: MFC42DBF120DEN

Abstracts

The Mexico cell and gene therapy market size reached USD 379.2 Million in 2025 . Looking forward, IMARC Group expects the market to reach USD 1,662.7 Million by 2034 , exhibiting a growth rate (CAGR) of 17.31 % during 2026-2034 . The market is driven by the rising prevalence of chronic disorders like cancer, diabetes, and orphan genetic diseases, unprecedented advances in biomedical research and development (R&D), and development of dedicated guidelines, and fast-track approval mechanisms for treatments targeting high-unmet medical needs or orphan diseases.

MEXICO CELL AND GENE THERAPY MARKET TRENDS:

Growing Prevalence of Chronic and Genetic Disorders

The rising prevalence of chronic disorders like cancer, diabetes, and orphan genetic diseases in Mexico is driving the need for innovative therapeutics, such as cell and gene therapies. These new treatments have the potential to cure or improve conditions that were previously considered incurable. For example, inherited diseases like hemophilia, sickle cell anemia, and lysosomal storage diseases are being addressed through gene therapies for correcting or substituting defective genes. Likewise, cell therapies using stem cells or Chimeric Antigen Receptor T-cell (CAR-T cells) are transforming oncology by expanding the immune system's capacity for recognizing and targeting tumor cells. This increasing disease burden is also fueling patient and healthcare professional interest in curative rather than lifelong management of symptoms. Consequently, the demand for novel biotechnological solutions and in-vitro diagnostics is accelerating, propelling the market growth. Furthermore, the IMARC Group predicts that the Mexico in-vitro diagnostics market size is expected to reach

USD 3.5 Billion by 2033.

Advancements in Research and Local Biotech Infrastructure

Mexico is experiencing unprecedented advances in biomedical research and development (R&D), which are very important for developing and marketing cell and gene therapies. Universities like the National Autonomous University of Mexico (UNAM) and institutes like the National Institute of Genomic Medicine (INMEGEN) are all actively engaging in genetic studies, clinical trials, and translational medicine. These institutions not only promote innovation but also act as training centers for talented professionals in cell and molecular biology. In addition, the Mexican government and private investors are increasingly investing in the development of infrastructure, such as specialized laboratories, bioprocessing facilities, and clinical-grade manufacturing plants. These investments are critical to increase production scale and guarantee regulatory compliance for ATMPs. In 2024, President Claudia Sheinbaum unveiled the New Consolidated Procurement Model for Medicines and Medical Supplies for the 2025-2026 timeframe, which will require an investment of 130 billion pesos.

Regulatory Support and International Collaborations

Mexico's regulatory framework is getting updated to support the intricacies of cell and gene therapies. The Federal Commission for the Protection against Sanitary Risk (COFEPRIS) is actively working to streamline clinical trial approvals and commercialization of advanced treatments. This entails the development of dedicated guidelines and fast-track approval mechanisms for treatments targeting high-unmet medical needs or orphan diseases. These regulatory improvements have the purpose to balance innovation with patient safety so that the business climate becomes favorable for biopharmaceutical investment. In addition, Mexico is actively participating in global partnerships with North American and European biotechnology companies. Such alliances enable knowledge exchange, access to advanced technologies, and involvement in global clinical trials. The blend of regulatory flexibility and international integration greatly enhances the market's potential and its congruence with global standards. In 2025, Stem Vitality Mexico started accepting new patients who are looking for safe and effective stem cell therapy for various conditions. By providing treatments at a fraction of the price usually found in the United States and Canada, the clinic offers an affordable alternative for those dealing with chronic pain, autoimmune diseases, orthopedic conditions, and age-related problems. Foreign patients are assisted by Stem Vitality Mexico's medical tourism program, which features complimentary initial consultations, bilingual care coordinators, and complete travel assistance, providing a

hassle-free experience from the San Diego border to the doors of the clinic.

MEXICO CELL AND GENE THERAPY MARKET SEGMENTATION:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the region level for 2026-2034. Our report has categorized the market based on therapy type, indication, delivery mode, and end user.

Therapy Type Insights:

Cell Therapy

Stem Cell Pluripotent Stem Cell Cancer Stem Cell Adult Stem Cell

Non-Stem Cell T-Cell Natural Killer Cell Others

Gene Therapy

Stem Cell

Pluripotent Stem Cell

Cancer Stem Cell

Adult Stem Cell

Non-Stem Cell

T-Cell

Natural Killer Cell

Others

The report has provided a detailed breakup and analysis of the market based on the therapy type. This includes cell therapy {stem cell (pluripotent stem cell, cancer stem cell, and adult stem cell) and non-stem cell (T-cell, natural killer cell, and others)} and gene therapy.

Indication Insights:

Cardiovascular Disease

Oncology Disorder

Genetic Disorder

Infectious Disease

Neurological Disorder

A detailed breakup and analysis of the market based on the indication have also been provided in the report. This includes cardiovascular disease, oncology disorder, genetic disorder, infectious disease, neurological disorder, and others.

Delivery Mode Insights:

In-Vivo

Ex-Vivo

A detailed breakup and analysis of the market based on the delivery mode have also been provided in the report. This includes in-vivo and ex-vivo.

End User Insights:

Hospitals

Cancer Care Centers

Pharmaceutical and Biotechnology Companies

A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospitals, cancer care centers, pharmaceutical and

biotechnology companies, and others.

Regional Insights:

Northern Mexico

Central Mexico

Southern Mexico

The report has also provided a comprehensive analysis of all the major regional markets, which include Northern Mexico, Central Mexico, Southern Mexico, and others.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

KEY QUESTIONS ANSWERED IN THIS REPORT

How has the Mexico cell and gene therapy market performed so far and how will it perform in the coming years?

What is the breakup of the Mexico cell and gene therapy market on the basis of therapy type?

What is the breakup of the Mexico cell and gene therapy market on the basis of indication?

What is the breakup of the Mexico cell and gene therapy market on the basis of delivery mode?

What is the breakup of the Mexico cell and gene therapy market on the basis of end user?

What is the breakup of the Mexico cell and gene therapy market on the basis of region?

What are the various stages in the value chain of the Mexico cell and gene therapy market?

What are the key driving factors and challenges in the Mexico cell and gene therapy market?

What is the structure of the Mexico cell and gene therapy market and who are the key players?

What is the degree of competition in the Mexico cell and gene therapy market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 MEXICO CELL AND GENE THERAPY MARKET - INTRODUCTION

- 4.1 Overview
- 4.2 Market Dynamics
- 4.3 Industry Trends
- 4.4 Competitive Intelligence

5 MEXICO CELL AND GENE THERAPY MARKET LANDSCAPE

- 5.1 Historical and Current Market Trends (2020-2025)
- 5.2 Market Forecast (2026-2034)

6 MEXICO CELL AND GENE THERAPY MARKET - BREAKUP BY THERAPY TYPE

- 6.1 Cell Therapy
 - 6.1.1 Overview
 - 6.1.2 Historical and Current Market Trends (2020-2025)
 - 6.1.3 Market Segmentation
 - 6.1.3.1 Stem Cell
 - 6.1.3.1.1 Pluripotent Stem Cell
 - 6.1.3.1.2 Cancer Stem Cell

- 6.1.3.1.3 Adult Stem Cell
- 6.1.3.2 Non-Stem Cell
 - 6.1.3.2.1 T-Cell
 - 6.1.3.2.2 Natural Killer Cell
 - 6.1.3.2.3 Others
- 6.1.4 Market Forecast (2026-2034)
- 6.2 Gene Therapy
 - 6.2.1 Overview
 - 6.2.2 Historical and Current Market Trends (2020-2025)
 - 6.2.3 Market Forecast (2026-2034)

7 MEXICO CELL AND GENE THERAPY MARKET - BREAKUP BY INDICATION

- 7.1 Cardiovascular Disease
 - 7.1.1 Overview
 - 7.1.2 Historical and Current Market Trends (2020-2025)
 - 7.1.3 Market Forecast (2026-2034)
- 7.2 Oncology Disorder
 - 7.2.1 Overview
 - 7.2.2 Historical and Current Market Trends (2020-2025)
 - 7.2.3 Market Forecast (2026-2034)
- 7.3 Genetic Disorder
 - 7.3.1 Overview
 - 7.3.2 Historical and Current Market Trends (2020-2025)
 - 7.3.3 Market Forecast (2026-2034)
- 7.4 Infectious Disease
 - 7.4.1 Overview
 - 7.4.2 Historical and Current Market Trends (2020-2025)
 - 7.4.3 Market Forecast (2026-2034)
- 7.5 Neurological Disorder
 - 7.5.1 Overview
 - 7.5.2 Historical and Current Market Trends (2020-2025)
 - 7.5.3 Market Forecast (2026-2034)
- 7.6 Others
 - 7.6.1 Historical and Current Market Trends (2020-2025)
 - 7.6.2 Market Forecast (2026-2034)

8 MEXICO CELL AND GENE THERAPY MARKET - BREAKUP BY DELIVERY MODE

8.1 In-Vivo

8.1.1 Overview

8.1.2 Historical and Current Market Trends (2020-2025)

8.1.3 Market Forecast (2026-2034)

8.2 Ex-Vivo

8.2.1 Overview

8.2.2 Historical and Current Market Trends (2020-2025)

8.2.3 Market Forecast (2026-2034)

9 MEXICO CELL AND GENE THERAPY MARKET - BREAKUP BY END USER

9.1 Hospitals

9.1.1 Overview

9.1.2 Historical and Current Market Trends (2020-2025)

9.1.3 Market Forecast (2026-2034)

9.2 Cancer Care Centers

9.2.1 Overview

9.2.2 Historical and Current Market Trends (2020-2025)

9.2.3 Market Forecast (2026-2034)

9.3 Pharmaceutical and Biotechnology Companies

9.3.1 Overview

9.3.2 Historical and Current Market Trends (2020-2025)

9.3.3 Market Forecast (2026-2034)

9.4 Others

9.4.1 Historical and Current Market Trends (2020-2025)

9.4.2 Market Forecast (2026-2034)

10 MEXICO CELL AND GENE THERAPY MARKET – BREAKUP BY REGION

10.1 Northern Mexico

10.1.1 Overview

10.1.2 Historical and Current Market Trends (2020-2025)

10.1.3 Market Breakup by Therapy Type

10.1.4 Market Breakup by Indication

10.1.5 Market Breakup by Delivery Mode

10.1.6 Market Breakup by End User

10.1.7 Key Players

10.1.8 Market Forecast (2026-2034)

10.2 Central Mexico

- 10.2.1 Overview
- 10.2.2 Historical and Current Market Trends (2020-2025)
- 10.2.3 Market Breakup by Therapy Type
- 10.2.4 Market Breakup by Indication
- 10.2.5 Market Breakup by Delivery Mode
- 10.2.6 Market Breakup by End User
- 10.2.7 Key Players
- 10.2.8 Market Forecast (2026-2034)
- 10.3 Southern Mexico
 - 10.3.1 Overview
 - 10.3.2 Historical and Current Market Trends (2020-2025)
 - 10.3.3 Market Breakup by Therapy Type
 - 10.3.4 Market Breakup by Indication
 - 10.3.5 Market Breakup by Delivery Mode
 - 10.3.6 Market Breakup by End User
 - 10.3.7 Key Players
 - 10.3.8 Market Forecast (2026-2034)
- 10.4 Others
 - 10.4.1 Historical and Current Market Trends (2020-2025)
 - 10.4.2 Market Forecast (2026-2034)

11 MEXICO CELL AND GENE THERAPY MARKET – COMPETITIVE LANDSCAPE

- 11.1 Overview
- 11.2 Market Structure
- 11.3 Market Player Positioning
- 11.4 Top Winning Strategies
- 11.5 Competitive Dashboard
- 11.6 Company Evaluation Quadrant

12 PROFILES OF KEY PLAYERS

- 12.1 Company A
 - 12.1.1 Business Overview
 - 12.1.2 Services Offered
 - 12.1.3 Business Strategies
 - 12.1.4 SWOT Analysis
 - 12.1.5 Major News and Events
- 12.2 Company B

- 12.2.1 Business Overview
- 12.2.2 Services Offered
- 12.2.3 Business Strategies
- 12.2.4 SWOT Analysis
- 12.2.5 Major News and Events
- 12.3 Company C
 - 12.3.1 Business Overview
 - 12.3.2 Services Offered
 - 12.3.3 Business Strategies
 - 12.3.4 SWOT Analysis
 - 12.3.5 Major News and Events
- 12.4 Company D
 - 12.4.1 Business Overview
 - 12.4.2 Services Offered
 - 12.4.3 Business Strategies
 - 12.4.4 SWOT Analysis
 - 12.4.5 Major News and Events
- 12.5 Company E
 - 12.5.1 Business Overview
 - 12.5.2 Services Offered
 - 12.5.3 Business Strategies
 - 12.5.4 SWOT Analysis
 - 12.5.5 Major News and Events

13 MEXICO CELL AND GENE THERAPY MARKET - INDUSTRY ANALYSIS

- 13.1 Drivers, Restraints, and Opportunities
 - 13.1.1 Overview
 - 13.1.2 Drivers
 - 13.1.3 Restraints
 - 13.1.4 Opportunities
- 13.2 Porters Five Forces Analysis
 - 13.2.1 Overview
 - 13.2.2 Bargaining Power of Buyers
 - 13.2.3 Bargaining Power of Suppliers
 - 13.2.4 Degree of Competition
 - 13.2.5 Threat of New Entrants
 - 13.2.6 Threat of Substitutes
- 13.3 Value Chain Analysis

14 APPENDIX

I would like to order

Product name: Mexico Cell and Gene Therapy Market Size, Share, Trends and Forecast by Therapy Type, Indication, Delivery Mode, End User, and Region, 2026-2034

Product link: <https://marketpublishers.com/r/MFC42DBF120DEN.html>

Price: US\$ 3,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MFC42DBF120DEN.html>